Acute and chronic pain dual pipeline enters a critical period, focusing on Latigo (LTGO.US), a non-opioid analgesic drug, seeking to land on Nasdaq and raise $100 million.

A biotechnology company, Latigo Biotherapeutics, which has met the conditions for entering Phase III clinical trials and is dedicated to the efficient development of non-opioid oral therapy for the treatment of acute and chronic pain, filed for an IPO with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to $100 million through an initial public offering. Latigo Biotherapeutics is a clinical-stage biotechnology leader dedicated to developing non-opioid analgesics targeting the Nav1.8 sodium ion channel. Its main candidate drug LTG-001 is an oral Nav1.8 inhibitor used to treat moderate to severe acute pain, including post-operative pain. The drug recently announced positive top-line data from a study of 343 patients undergoing abdominal plastic surgery, achieving the primary SPID48 endpoint compared to placebo. Latigo Biotherapeutics' two most advanced candidate drugs, LTG-001 and LTG-321, are both oral Nav1.8 inhibitors aimed at inhibiting the transmission of pain signals. The company is also aggressively advancing the development of other Nav1.8 candidate drugs to explore different formulations and routes of administration. In addition to Nav1.8, the company plans to explore other ion channel targets involved in pain signal transmission in the future, which have complementary mechanisms of action and may be used for multimodal therapy to enhance analgesic effects or address various causes of pain. The main candidate product LTG-001 is an oral Nav1.8 inhibitor designed to provide rapid relief for acute pain with fewer opioid drugs. LTG-001 is currently in development as a potential treatment for moderate to severe acute pain (including post-operative pain) and is planned to be used for up to 30 days as needed. LTG-321 is the company's next-generation candidate drug inhibiting Nav1.8, initially for the treatment of chronic musculoskeletal pain, starting with osteoarthritis (OA). This cutting-edge biotechnology company plans to conduct a placebo-controlled Phase III trial for bunionectomy surgery in the second half of 2026, as well as an open-label Phase III safety trial, with top-line clinical trial results expected to be announced in the second half of 2027. LTG-321, the company's second Nav1.8 candidate drug, is intended for the treatment of chronic musculoskeletal pain, initially targeting indications starting with osteoarthritis, and is currently undergoing a Phase II concept validation trial, with results expected to be announced in the second half of 2027. The company's earlier-stage development pipeline also includes the pre-clinical Nav1.8 inhibitor LTG-418, as well as discovery-stage projects targeting ion channels involved in pain transmission. Headquartered in Thousand Oaks, California, the company was founded in 2018 and plans to list on the U.S. NASDAQ stock market under the ticker symbol "LTGO." Latigo Biotherapeutics secretly submitted its IPO listing application to the U.S. stock market on March 27, 2026. Goldman Sachs, J.P. Morgan, Leerink Partners, and Guggenheim Securities are acting as joint bookrunners for this transaction.